Form 4: Spruce Biosciences Chief Medical Officer Reports Stock Transactions Following RSU Vesting
SEC Form 4 Filing
Spruce Biosciences' Chief Medical Officer, Ralph William Charlton III, reports multiple transactions involving the vesting and subsequent tax withholding of restricted stock units (RSUs).
Summary
- Ralph William Charlton III, Chief Medical Officer of Spruce Biosciences, reported several transactions related to his restricted stock units (RSUs).
- On December 10, 2024, 106,400 performance-based RSUs vested, and a corresponding number of shares were acquired.
- On December 10, 2024, 37,964 shares were withheld for taxes related to the vesting of the performance-based RSUs at a price of $0.537 per share.
- On December 16, 2024, 26,600 time-based RSUs vested, and a corresponding number of shares were acquired.
- On December 16, 2024, 9,491 shares were withheld for taxes related to the vesting of the time-based RSUs at a price of $0.3887 per share.
- On December 16, 2024, an additional 31,750 time-based RSUs vested, and a corresponding number of shares were acquired.
- On December 16, 2024, 11,329 shares were withheld for taxes related to the vesting of the additional time-based RSUs at a price of $0.3887 per share.
- The transactions resulted in a net increase of 17,109 shares from the first time-based RSU vesting and 20,421 shares from the second time-based RSU vesting.
Sentiment
Score: 7
Explanation: The document reflects standard executive compensation practices and does not indicate any positive or negative news. The vesting of RSUs is a normal part of the compensation plan.
Positives
- The vesting of performance-based RSUs indicates that certain performance goals were met.
- The vesting of time-based RSUs is part of the standard compensation plan for the executive.
Industry Context
This is a standard SEC Form 4 filing, which is common for publicly traded companies when executives have transactions involving company stock, particularly related to equity compensation.
Comparison to Industry Standards
- The vesting of RSUs is a common practice in the biotechnology industry as part of executive compensation packages.
- Companies like BioMarin Pharmaceutical and Vertex Pharmaceuticals also use RSUs as part of their compensation strategy.
- The tax withholding of shares upon vesting is a standard procedure to cover the tax obligations of the employee.
Stakeholder Impact
- The transactions have a minor dilutive effect on existing shareholders due to the issuance of new shares.
- The vesting of RSUs is a positive for the executive as it is part of their compensation.
Key Dates
| Date | Description |
|---|---|
| 2022-12-05 | Date of grant of 127,000 time-based RSUs. |
| 2023-12-14 | Date of grant of 212,800 RSUs, 50% performance-based and 50% time-based. |
| 2023-12-15 | First annual vesting date for the 2022 time-based RSUs. |
| 2024-12-10 | Date of vesting of performance-based RSUs. |
| 2024-12-15 | Date of vesting of the first tranche of the 2023 time-based RSUs. |
| 2024-12-16 | Date of vesting of the second tranche of the 2023 time-based RSUs. |
| 2024-12-20 | Date of filing of the Form 4. |
Keywords
RSU, Restricted Stock Units, Spruce Biosciences, Insider Trading, Form 4, Equity Compensation, Vesting, Chief Medical Officer
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.